Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ARCHIVE
ARCHIVE
- FDA Is Very Interested in Immediate PMS System: Dr Kurokawa of PFSB
February 18, 2002
- Korosho to Accept STED-based Applications for Medical Devices
February 18, 2002
- Korosho to Allow Hospitals to Charge Special Medical Treatment Fee for Unlisted Drugs
February 18, 2002
- Court Rejects Taisho's Demands in Lawsuit Against Daikoku
February 18, 2002
- Legal Drug Classification to Be Revised
February 18, 2002
- 49% Rise in Operating Profits Expected for Ain Pharmaciez: Nomura Report
February 18, 2002
- P&G to Sell Vicks Medicated Drop Business
February 11, 2002
- REGULATORY NEWS IN BRIEF
February 11, 2002
- Olympus Develops DNA Computer for Gene Analysis
February 11, 2002
- Yamanouchi, Sumitomo Chemical Tie Up on Knockout Mice with Transgenic Inc
February 11, 2002
- Eiken Develops New Bovine Embryo Sexing Reagent
February 11, 2002
- Tanabe Ties Up with Menarini to Develop Antitumor Agent
February 11, 2002
- BML to Merge 2 Subsidiaries
February 11, 2002
- Mochida to Expand Its Business Fields
February 11, 2002
- LDP to Review Safety Measures against Medical Devices
February 11, 2002
- Sankyo to Beef Up Business Development in China
February 11, 2002
- Shimadzu: Multi-channel Oxygen Monitors
February 11, 2002
- WEBSITE NEWS
February 11, 2002
- Brand Generic Business Likely to Be Brisk
February 11, 2002
- BUSINESS NEWS IN BRIEF
February 11, 2002
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…